Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ).
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has issued an update on its continuous risk assessment report concerning its subsidiary, Tianjin Pharmaceutical Group Finance Co., Ltd. This update follows the Shanghai Stock Exchange’s requirements for listed companies to issue bi-annual risk assessment reports when engaging in transactions with related finance companies. The company has entered into a financial service agreement with TPGF for services including settlement, deposit, and credit business for a three-year period, highlighting its adherence to regulatory guidelines and commitment to transparency in financial dealings.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a company incorporated in the People’s Republic of China. It operates in the pharmaceutical industry and is involved in providing various financial services through its subsidiary, Tianjin Pharmaceutical Group Finance Co., Ltd.
See more data about 2TZ stock on TipRanks’ Stock Analysis page.